EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY
NEWS
Apellis Announces FDA Fast Track Designation for APL-2 in PNH
C3 inhibitor is in development for the treatment of PNH, both in patients not previously treated with eculizumab, and in patients who continue to experience
Mironid and University of Sheffield Collaborate on Kidney Disease Drug Discovery
Glasgow, Scotland, and Sheffield, UK, 12th December 2016 – Mironid Ltd, a leader in cell signalling-directed drug development, and the University of Sheffield, announced today
Mironid is Delighted to Announce that Prof Albert Ong Has Joined Our Scientific Advisory Board
Mironid is delighted to announce that Prof Albert Ong DM MA FRCP, Professor of Renal Medicine, Department of Infection Immunity & Cardiovascular Disease, University of
Apellis Reports Positive Interim Results from Phase Ib Clinical Trials of APL-2 in PNH
Louisville, Ky., December 2, 2016 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on inhibition of the complement system, today will present positive interim
Enterprise Therapeutics Announces £4 million ($5 million USD) Fundraising
Brighton, UK, November 10, 2016: Enterprise Therapeutics Ltd, a drug discovery company dedicated to the research and development of novel therapies for the treatment of
Elizabeth Roper Selected for BioBeat’s 50 Movers and Shakers in BioBusiness for 2016
Epidarex is honored to have Elizabeth Roper, Partner, selected as one of the 50 Movers and Shakers in BioBusiness for 2016 from the Cambridge, UK-based
Invest Edinburgh Interview with Elizabeth Roper – Biotech Company Nodthera Launched in Edinburgh
Originally published October 31, 2016 in Invest Edinburgh A new biotech company called Nodthera has been launched in Edinburgh to develop potential treatments for a
Clyde Launches New Contractility Service – CellOPTIQ®-X
Newhouse, United Kingdom, October 26, 2016 – Clyde Biosciences today announced the launch of a new service to serve the needs of its global pharma